Evidence map›Paper›PMID 38561253›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024

Antidepressant use in relation to dementia risk, cognitive decline, and brain atrophy.

Ilse Vom Hofe, Bruno H Stricker, Meike W Vernooij, M Kamran Ikram, M Arfan Ikram, Frank J Wolters

Open access · hybridAbstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Antidepressant use in relation to dementia risk, cognitive decline, and brain atrophy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ilse Vom HofeDepartment of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0002-4212-7718
Bruno H StrickerDepartment of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Meike W VernooijDepartment of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands.
M Kamran IkramDepartment of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands.
M Arfan IkramDepartment of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Frank J WoltersDepartment of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands.ORCID 0000-0003-2226-4050
Erasmus MC · NL

Funding

Alzheimer NederlandBrain & Behavior Research FoundationErasmus Medical Center and Erasmus University RotterdamEuropean CommissionMunicipality of RotterdamNetherlands Organization for the Health Research and DevelopmentResearch Institute for Diseases in the ElderlyStichting Erasmus Trustfonds 97030.2021.101.430/057/RBThe Dutch ministry for Health, Welfare and SportsThe Dutch ministry of Education, Culture and ScienceZonMW Memorabel 73305095005
6 · The paper itself

Abstract

introductionWe aimed to assess the effect of antidepressant use on dementia risk, cognitive decline, and brain atrophy.

methodsIn this prospective cohort study, we included 5511 dementia-free participants (Mini-Mental State Examination [MMSE] > 25) of the Rotterdam study (57.5% women, mean age 70.6 years). Antidepressant use was extracted from pharmacy records from 1991 until baseline (2002-2008). Incident dementia was monitored from baseline until 2018, with repeated cognitive assessment and magnetic resonance imaging (MRI) every 4 years.

resultsCompared to never use, any antidepressant use was not associated with dementia risk (hazard ratio [HR] 1.14, 95% confidence interval [CI] 0.92-1.41), or with accelerated cognitive decline or atrophy of white and gray matter. Compared to never use, dementia risk was somewhat higher with tricyclic antidepressants (HR 1.36, 95% CI 1.01-1.83) than with selective serotonin reuptake inhibitors (HR 1.12, 95% CI 0.81-1.54), but without dose-response relationships, accelerated cognitive decline, or atrophy in either group. DISCUSSION: Antidepressant medication in adults without indication of cognitive impairment was not consistently associated with long-term adverse cognitive effects. HIGHLIGHTS: Antidepressant medications are frequently prescribed, especially among older adults. In this study, antidepressant use was not associated with long-term dementia risk. Antidepressant use was not associated with cognitive decline or brain atrophy. Our results support safe prescription in an older, cognitively healthy population.

Indexed as

Antidepressive AgentsAtrophyBrainCognitive DysfunctionDementiaMagnetic Resonance ImagingAgedFemaleHumansMaleMiddle AgedProspective StudiesRisk FactorsAntidepressive Agentsantidepressant usecognitive declinedepressionMRIpopulation‐based

Identifiers

PMID38561253
PMCPMC11095425
OpenAlexW4394750643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.